Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

121. A self help guidebook reduced primary care consultations in irritable bowel syndrome

A self help guidebook reduced primary care consultations in irritable bowel syndrome A self help guidebook reduced primary care consultations in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A self help guidebook reduced primary care consultations in irritable bowel syndrome Article Text Therapeutics A self help guidebook reduced primary care consultations in irritable bowel syndrome Statistics from

2006 Evidence-Based Medicine

122. Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Full Text available with Trip Pro

Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Article Text Therapeutics Review: soluble fibre

2005 Evidence-Based Medicine

123. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. Full Text available with Trip Pro

Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. To assess the efficacy of cognitive behaviour therapy delivered in primary care for treating irritable bowel syndrome.Randomised controlled trial.10 general practices in London.149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine.Cognitive behaviour therapy delivered by trained primary care nurses plus (...) 270 mg mebeverine taken thrice daily compared with mebeverine treatment alone.Primary measures were patients' scores on the irritable bowel syndrome symptom severity scale. Secondary measures were scores on the work and social adjustment scale and the hospital anxiety and depression scale.Of 334 referred patients, 72 were randomised to mebeverine plus cognitive behaviour therapy and 77 to mebeverine alone. Cognitive behaviour therapy had considerable initial benefit on symptom severity compared

2005 BMJ Controlled trial quality: predicted high

124. Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Full Text available with Trip Pro

Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Tan G, Hammond D C, Gurrala J CRD summary This review concluded that variations on a protocol for hypnosis represent an effective therapy for reducing symptoms of irritable bowel syndrome and improving emotional and quality-of-life outcomes (...) in the long term. Several significant limitations in the review process, along with the paucity of the evidence reviewed, suggest that the authors' conclusions may be overstated and not particularly robust. Authors' objectives To assess the efficacy of hypnosis in reducing the symptoms and in improving emotional and quality-of-life outcomes associated with irritable bowel syndrome (IBS), and to examine the possible mechanisms of action. Searching The authors searched PubMed and PsycLIT, along with medical

2005 DARE.

125. Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Full Text available with Trip Pro

Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Article Text Economics

2004 Evidence-Based Medicine

126. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Full Text available with Trip Pro

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Irritable bowel syndrome (IBS), which affects 11% to 14% of the population, is a puzzling condition with multiple models of pathophysiology including altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation. Although no conceptual framework accounts for all the symptoms and observations in IBS, a unifying explanation may exist since 92 (...) between the pattern of bowel movement and the type of excreted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvement of IBS symptoms after eradication of SIBO. Altered gastrointestinal motility and sensation, changed activity of the central nervous system, and increased sympathetic drive and immune activation may be understood as consequences of the host response to SIBO.The gastrointestinal and immune effects of SIBO provide a possible unifying framework

2004 JAMA

127. General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study. Full Text available with Trip Pro

General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: qualitative study. To compare general practitioners' perceptions of chronic fatigue syndrome and irritable bowel syndrome and to consider the implications of their perceptions for treatment.Qualitative analysis of transcripts of group discussions.A randomly selected sample of 46 general practitioners in England.The participants tended to stereotype patients (...) participants would not consider referral for mental health interventions, even though the doctors recognised social and psychological factors, because they were not familiar with the interventions or thought them unavailable or unnecessary.Barriers to the effective clinical management of patients with irritable bowel syndrome and chronic fatigue syndrome are partly due to doctors' beliefs, which result in negative stereotyping of patients with chronic fatigue syndrome and the use of management strategies

2004 BMJ

128. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

129. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis

, Dulai G S. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126(7): 1721-1732 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Celiac Disease /diagnosis /economics /epidemiology /prevention & Cost-Benefit Analysis; Diarrhea /diagnosis /economics; Diet; Glutens; Humans; Irritable Bowel Syndrome /diagnosis /economics /epidemiology /prevention & Mass Screening /economics; Prevalence; Sensitivity (...) Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Spiegel B M R, DeRosa V P, Gralnek I M, Wang V, Dulai G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

2004 NHS Economic Evaluation Database.

130. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Full Text available with Trip Pro

Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis Mein S M, Ladabaum U Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) with symptoms consistent with a diagnosis of IBS (irritable bowel syndrome) at acceptable cost per case detected and per QALY (quality-adjusted life-year) gained". Up-front oesophago-gastroduedenoscopy (EGD) plus biopsy in all patients with symptoms of IBS was always dominated by serological testing. CRD COMMENTARY - Selection of comparators The authors did not justify their choice of the comparators. However, no testing for coeliac disease in patients with suspected IBS would seem to represent the standard

2004 NHS Economic Evaluation Database.

131. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Cremonini F, Delgado-Aros S, Camilleri M CRD summary This review analysed six trials on the effects of alosetron in irritable bowel syndrome (IBS). The authors concluded that alosetron can improve (...) symptoms or decrease pain in female IBS patients without constipation. However, they also concluded that alosetron can have adverse effects, particularly constipation. The effects in men are unclear. These conclusions are appropriate given the evidence available. Authors' objectives To determine the effect of alosetron therapy on adequate relief of pain or global improvement of symptoms in patients with irritable bowel syndrome (IBS). Searching MEDLINE (from 1966 to 2002) and EMBASE (from 1988 to 2002

2003 DARE.

132. A systematic review of alternative therapies in the irritable bowel syndrome

implications for practice. Research: The authors stated that well-designed trials are required in this area. Bibliographic details Spanier J A, Howden C W, Jones M P. A systematic review of alternative therapies in the irritable bowel syndrome. Archives of Internal Medicine 2003; 163(3): 265-274 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Behavior Therapy; Colonic Diseases, Functional /diet therapy /etiology /microbiology /psychology /therapy; Combined Modality Therapy (...) A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome A systematic review of alternative therapies in the irritable bowel syndrome Spanier J A, Howden C W, Jones M P CRD summary This review concluded that there is no strong evidence for the effectiveness of alternative therapies in the treatment of irritable bowel syndrome. This was a poorly conducted review and it is unlikely that the findings

2003 DARE.

133. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

134. Irritable bowel syndrome: a little understood organic bowel disease? (Abstract)

Irritable bowel syndrome: a little understood organic bowel disease? Irritable bowel syndrome affects 10% of adults with an unexplained female predominance. Although only a few people see their family doctor, the disease causes reduced quality of life and represents a multi-billion pound health-care problem. The disorder clusters in families, which is possibly because of intra-familial learning and a genetic predisposition. Visceral hypersensitivity is a key feature in most patients. Results (...) of imaging studies of regional cerebral blood flow during rectal distension suggest underlying disturbances of central processing of afferent signals, though this is not unique to the disorder, since it is seen in other chronic pain syndromes. Environmental factors that are strongly implicated in at least some patients include gastrointestinal infection and inflammation and chronic stress. Diagnosis is based on positive symptoms and absence of any alarm indicators. Treatment remains unsatisfactory

2002 Lancet

135. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 DARE.

136. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. (Abstract)

Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Irritable bowel syndrome has a high prevalence. Consensus diagnostic criteria (ROME II) based on symptoms have been established to aid diagnosis. Although coeliac disease can be misdiagnosed as irritable bowel syndrome, no prospective study has been published in which patients with this disorder are investigated for coeliac disease. We (...) aimed to assess the association of coeliac disease with irritable bowel syndrome in patients fulfilling ROME II criteria.We undertook a case-control study at a university hospital. 300 consecutive new patients who fulfilled Rome II criteria for irritable bowel syndrome, and 300 healthy controls (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, IgG antigliadin, and endomysial antibodies (EMA). Patients and controls with positive antibody results were

2001 Lancet

137. Tegaserod (Zelmac) (irritable bowel syndrome)

Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Tegaserod (Zelmac) (irritable bowel syndrome) Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Tegaserod (Zelmac) (irritable bowel syndrome) University HealthSystem Consortium (UHC). Drug Monograph. 2001 Authors' objectives The UHC Drug Monographs (...) advantages, and they address issues concerning therapeutic interchange. Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Colonic Diseases, Functional /drug therapy Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954

2001 Health Technology Assessment (HTA) Database.

138. Cost-effectiveness of endoscopy in irritable bowel syndrome

be reserved for patients in whom high diagnostic certainty is deemed necessary. Source of funding None stated. Bibliographic details Suleiman S, Sonnenberg A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Archives of Internal Medicine 2001; 161: 369-375 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Colonic Diseases, Functional /diagnosis /economics; Colonoscopy /economics; Cost-Benefit Analysis; Decision Trees; Humans; Predictive Value of Tests; Sigmoidoscopy /economics (...) Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Suleiman S, Sonnenberg A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

2001 NHS Economic Evaluation Database.

139. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

and reduce pain in irritable bowel syndrome. Evid Based Med 2001;6:153. Indexing Status Subject indexing assigned by NLM MeSH Abdominal Pain /drug therapy /etiology; Adult; Colonic Diseases, Functional /drug therapy /pathology; Female; Humans; Male; Middle Aged; Odds Ratio; Parasympatholytics /pharmacology /therapeutic use; Placebos; Treatment Outcome AccessionNumber 12001000657 Date bibliographic record published 30/06/2002 Date abstract record published 30/06/2002 Record Status This is a critical (...) . The keywords used were 'colonic disease', 'functional', irritable bowel syndrome' and 'randomised trial'. Additional studies were obtained by examining general reviews, references from published RCTs, and Current Contents, and by contacting pharmaceutical companies. In addition, recent meta-analyses in the Journal of Hepatogastroenterology were also used. Only published articles were considered for the review. Study selection Study designs of evaluations included in the review Only double-blind, placebo

2001 DARE.

140. Treatment of irritable bowel syndrome: a review of randomised controlled trials

Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Treatment of irritable bowel syndrome: a review of randomised controlled trials Akehurst R, Kaltenthaler E Authors' objectives To review and assess published randomised controlled trials (RCTs) examining the clinical effectiveness of interventions for irritable bowel syndrome (IBS) treatments. Searching The Cochrane Library, DARE (...) of this review. Research: The authors state that 'it is essential that RCTs are conducted of consistently identified patients with clearly defined outcome measures. These outcome measures should not only deal with symptom relief but also improvement in quality of life and associated measures such as time off work'. Bibliographic details Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48(2): 272-282 PubMedID Original Paper URL Other

2001 DARE.